# C_2019307EN.01001101.xml

| 11.9.2019 | EN | Official Journal of the European Union | C 307/11 |
| --- | --- | --- | --- |

11.9.2019

EN

Official Journal of the European Union

C 307/11

---

Prior notification of a concentration

(Case M.9525 — EPE/OCH/Omnicare)

Candidate case for a simplified procedure

(Text with EEA relevance)

(2019/C 307/08)

1.

This notification concerns the following undertakings:

| — | Equistone Partners Europe Limited (‘Equistone’, United Kingdom), |
| --- | --- |

—

Equistone Partners Europe Limited (‘Equistone’, United Kingdom),

| — | Omnicare Holding GmbH & Co. KG (‘OCH’, Germany), |
| --- | --- |

—

Omnicare Holding GmbH & Co. KG (‘OCH’, Germany),

| — | Omnicare Beteiligungen GmbH (‘Omnicare’, Germany). |
| --- | --- |

—

Omnicare Beteiligungen GmbH (‘Omnicare’, Germany).

The proposed concentration consist of the acquisition of joint control, within the meaning of Articles 3(1)(b) and 3(4) of the Merger Regulation, by Equistone and OCH over Omnicare.

The concentration is accomplished by way of purchase of shares.

2.

| — | Equistone is a private equity investment firm active in the United Kingdom, France, Germany and Switzerland. Funds controlled by Equistone are investing in companies from various business sectors such as consumer and travel, financial services, specialist engineering and support services, |
| --- | --- |

—

Equistone is a private equity investment firm active in the United Kingdom, France, Germany and Switzerland. Funds controlled by Equistone are investing in companies from various business sectors such as consumer and travel, financial services, specialist engineering and support services,

| — | Omnicare is mainly active in: (i) specialty pharma distribution (oncological pharmaceutical products), (ii) services for compounding pharmacies, (iii) holding of participations in certain outpatient oncological medical centres and (iv) clinics for treatment of mental and psychosomatic disorders and diseases. |
| --- | --- |

—

Omnicare is mainly active in: (i) specialty pharma distribution (oncological pharmaceutical products), (ii) services for compounding pharmacies, (iii) holding of participations in certain outpatient oncological medical centres and (iv) clinics for treatment of mental and psychosomatic disorders and diseases.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9525 — EPE/OCH/Omnicare

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

| Email: COMP-MERGER-REGISTRY@ec.europa.eu |
| --- |
| Fax +32 22964301 |
| Postal address: |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---